MLMartin Little

Martin Little

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Martin Little has a total of 196 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lymphocyte Stability Following Immune Checkpoint Blockade Is Coupled to Mitochondrial Haplogroup and Clinical Outcome in Advanced Melanoma

    by Shawn Sun, Maksim C.F. Chan, Robert A. Watson, Sophie MacKay, Martin Little, Orion Tong, Andrea Farkas, Guangyi Niu, Lea R.Z. Cohen, Gusztav Milotay, et al.

    Summary: Early biomarkers of durable response to immune checkpoint blockade (ICB) are urgently needed. We identify lymphocyte stability (LS) – preservation of peripheral lymphocyte counts after one cycle of ICB – as an on-treatment predictor of overall survival (OS) in metastatic melanoma (MM): patients with unstable lymphocyte counts (LS-U; post-ICB/baseline ≤0.8) have markedly increased risk of death. Metabolic profiling of patient T cells demonstrates ICB enhancement of mitochondrial bioenergetics, whilst CD8+ T cells from LS-U patients mount an exaggerated transcriptional response to ICB incorporating upregulation of mitochondrial pathways. Given these findings we assessed the relationship of LS with mitochondrial haplogroup, revealing carriage of haplogroup T (HG-T), present in ∼10% of white British individuals, is associated with both LS-U and impaired OS, with mediation analysis implicating LS mediation. HG-T carriers have higher CD8+ T-cell pre-treatment mitochondrially encoded transcript abundance and, in paired scRNA-seq data, fewer progenitor-exhausted cells, ICB hyperresponsivity, apoptotic program induction and reduced clonal persistence – consistent with baseline mitochondrial priming. These findings position LS as a clinically accessible marker of ICB outcome linked to inherited mitochondrial variation. Highlights: - Lymphocyte stability is a pan-cancer predictor of survival and durable response following immune checkpoint blockade - ICB elicits coordinated mitochondrial transcriptional and functional responses in T cells - LS-U mediates the link between mitochondrial HG-T and poor overall survival following checkpoint immunotherapy - HG-T CD8+ T cells are transcriptionally primed at baseline but show enhanced apoptosis and reduced clonal persistence after ICB

  • Open Access

    Peripheral Biomarkers and Determinants of Survival for Patients with Melanoma Brain Metastasis Treated with Immune Checkpoint Blockade

    by Jasmine Hassan, Martin Little, Andrea Farkas, Sophie MacKay, Nicholas Anthony Coupe, Mark Ross Middleton, Miranda Jayne Payne, Benjamin Peter Fairfax

    Background: Immune checkpoint blockade (ICB) has become the standard of treatment for metastatic melanoma (MM). However, patients with melanoma brain metastases (MBM) are often excluded from clinical trials. Here we analyse patients within the real-world OxCITE cohort receiving ICB treatment for metastatic melanoma, with a focus on MBM, aiming to discern outcomes, prognostic factors and peripheral biomarkers. Methods: Patients eligible for ICB treatment were recruited prospectively. Demographic, clinical and radiological data were collected from electronic patient records. Plasma samples were collected prior to the first cycle of treatment for plasma proteomic analysis. Results: 307 patients were included, 81 of whom had MBM on commencing ICB. No difference in overall survival between patients with and without brain metastases was noted on multivariable analysis (HR=1.1, 95% CI 0.73-1.6, p=0.68), whereas hepatic metastases were associated with increased risk of death (HR 1.7, 95% CI 1.2-2.4, p=0.0019). Within the MBM group, steroid treatment (HR=2.5, 95% CI 1.3-5.0, p=0.006) was associated with poor OS, whilst treatment with single agent ICB (HR=1.9, 95% CI 0.86-3.9, p=0.11), symptomatic first presentation of MBM (HR=1.5, 95% CI 0.76-2.8, p=0.25) and anti-seizure drug treatment (HR=1.74, 95% CI 0.89-3.4, p=0.10) were not. Amongst all patients carriage of a BRAF mutation was associated with increased risk of MBM (OR 2.49, 95% CI 1.4-4.4, p=0.0007), and increased propensity to new brain metastases on ICB treatment (OR 2.5, 95% CI 1.1-5.9, p=0.036). Analysis of blood and plasma samples demonstrated that patients with MBM have altered haematological profiles, with raised NLR and increased plasma glial fibrillary acidic protein levels, reinforcing the distinct systemic features of MBM. Conclusions: In this real-world cohort of patients receiving ICB for metastatic melanoma, the presence of MBM did not associate with worse OS. Conversely, baseline corticosteroid use was adversely prognostic. Intriguingly, plasma GFAP was significantly elevated in patients with MBM and correlated with the burden of intracranial disease, highlighting a potential role for GFAP as a candidate biomarker for MBM in high-risk surveillance. Our observations indicate the adversely prognostic weight historically attached to M1d disease is no longer applicable in the ICB era.

  • Open Access

    Anti-CMV IgG titer determines organ-specific protection toward immune checkpoint blockade-induced toxicities

    by Gusztav Milotay, Martin Little, Sophie MacKay, Dylan Patrick Browne Muldoon, An-Nhi Huynh, Andrea Farkas, Shawn Sun, Guangyi Niu, Orion Tong, Chelsea A Taylor, et al.

    Background: Immune-related adverse events (irAEs) post-immune checkpoint blockade (ICB) are a leading cause of patient morbidity. Robust peripheral biomarkers of irAEs are required to improve patient stratification to existing treatment regimens, and these are currently lacking. Seropositivity for human cytomegalovirus (CMV) is associated with protection against severe (grade 3+) irAEs post-ICB; however, the impact of infection on systemic immunity is highly variable. Here, in a prospectively recruited pan-cancer ICB-treated cohort (n=472 patients), we investigate a novel relationship between the relative baseline titer of anti-CMV IgG antibody and organ-specific protection against irAEs. Methods: Peripheral blood samples were collected from 472 patients prior to and following one cycle of ICB. CMV serotyping was performed on plasma, while flow cytometry and single-cell RNA/V(D)J sequencing were performed on peripheral blood mononuclear cells. Bulk RNA-sequencing was performed on sorted CD8 + T cells. Serological and phenotyping data were integrated with long-term clinical follow-up of response and irAEs. Results: In CMV seropositive patients, whereas anti-CMV IgG antibody level demonstrates stability over years, high pretreatment titer is independently associated with reduced all-organ grade 3+ irAEs. This pan-organ association subdivides into organ-specific effects; protection against non-colitis irAEs being observed only in those with an above median titer of anti-CMV IgG antibody (P High titer vs CMV −=2.1×10 −4 ), whereas CMV-related protection against colitis is unrelated to titer (P Low titer =0.0012, P High titer =0.0031). We demonstrate that anti-CMV IgG antibody titer is robustly coupled to peripheral immune subset composition, with higher anti-CMV IgG titer associated with elevated CD4 + and CD8 + T cell cytotoxicity and effector cell expansion. Conversely, CMV seropositivity is associated with generally reduced circulating T regs cells irrespective of titer. Furthermore, we find exacerbated T cell receptor repertoire skewing toward the largest clones in High Titer individuals, with reduced survival of these clones following ICB treatment. Conclusions: This work reinforces the importance of CMV in modulating ICB-induced irAEs, revealing a complex relationship between the degree of humoral anti-CMV immunity and organ-specific protection, while further highlighting the clinical utility of CMV serology in predicting ICB-induced irAEs.

  • Open Access

    Anti-CMV IgG Titre Determines Organ-Specific Protection Towards Immune Checkpoint Blockade Induced Toxicities

    by Gusztav Milotay, Martin Little, Sophie MacKay, Dylan Muldoon, An-Nhi Huynh, Andrea Farkas, Shawn Sun, Guangyi Niu, Orion Tong, Chelsea A Taylor, et al.

    Seropositivity for human cytomegalovirus (CMV) is associated with protection against severe (Grade 3+) immune-related adverse events (irAEs) post Immune Checkpoint Blockade (ICB). Here, in a prospectively recruited pan-cancer ICB-treated cohort (n=448 patients), we identify a novel relationship between the relative baseline titre of anti-CMV IgG antibody and organ-specific protection against irAEs. In CMV seropositive patients, whereas anti-CMV IgG antibody level is stable over years, increased pre-treatment titre is independently associated with reduced all-organ Grade 3+ irAEs. This pan-organ association sub-divides into organ-specific effects; protection against non-colitis irAEs being observed only in those with an above median titre of anti-CMV IgG antibody ( P High titre vs. CMV − =2×10 −5 ), whereas CMV-related protection against colitis is unrelated to titre ( P Low titre =0.0016, P High titre =0.0012). We demonstrate that anti-CMV IgG antibody titre is robustly related to peripheral immune subset composition, with higher anti-CMV IgG titre associated with elevated CD4 + and CD8 + T cell cytotoxicity and effector cell expansion. Conversely, CMV seropositivity is associated with general reduced circulating Tregs irrespective of titre. This work reinforces the importance of CMV in modulating ICB-induced irAEs, revealing a complex relationship between degree of humoral anti-CMV immunity and organ-specific protection, whilst further highlighting the clinical utility of CMV serology in predicting ICB induced irAEs.

  • Open Access

    The immunomodulatory role of human cytomegalovirus in cancer in the era of checkpoint immunotherapy

    by Julia Bremke, Cecilia Jay, Martin Little, Benjamin P. Fairfax

    This review discusses the role of chronic human cytomegalovirus (HCMV) infection in patients receiving immune checkpoint blockade (ICB) treatment against different malignancies, with an especial focus on malignant melanoma. We briefly outline the impact of HCMV infection on the immune system as an entity before exploring its role in the context of cancer. We then address the potential impact on the efficacy of immunotherapeutic agents, particularly ICB, before looking at development of ICB-related autoimmune toxicity. Finally, we discuss potential avenues for future research. This article is part of the discussion meeting issue ‘The indirect effects of cytomegalovirus infection: mechanisms and consequences’.


  • Open Access

    Defining the genetic determinants of CD8 + T cell receptor repertoire in the context of immune checkpoint blockade

    by Esther S. Ng, Gusztav Milotay, Orion Tong, Chelsea A. Taylor, Shawn Sun, Guangyi Niu, Robert Watson, Bo Sun, Sophie MacKay, James J. Gilchrist, et al.

    The relationship between genetic variation and CD8 + T cell receptor (TCR) repertoire usage in patients receiving immune checkpoint blockade (ICB) therapy for cancer is unexplored. We have conducted a genome-wide and human leukocyte antigen (HLA)–focused analysis of CD8 + TCR repertoire to identify genetic determinants of variable gene (V-gene) and CDR3 K -nucleotide oligomer usage from samples taken before and after ICB ( n = 250). We identify 11 cis and 10 trans V-gene associations, primarily to the MHC, that meet genome-wide significance. TCR clones containing HLA associated V-genes were less stable across treatment, while, at the single-cell level, genetically associated clones demonstrate subset enrichment and increased tumor reactivity expression profiles. Notably, patients with HLA-matched TCR clones demonstrate improved overall survival. Our work indicates a complex relationship between genotype and TCR repertoire in the context of ICB treatment, with implications for understanding factors relating to therapeutic response and patient outcomes.


  • Open Access

    CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade

    by Gusztav Milotay, Martin Little, Robert A. Watson, Dylan Muldoon, Sophie MacKay, Ayako Kurioka, Orion Tong, Chelsea A. Taylor, Isar Nassiri, Louisa M. Webb, et al.

    Cytomegalovirus (CMV) is a globally endemic latent herpes virus that profoundly impacts T cell immunity. We investigated the oncological consequences of CMV infection across 341 prospectively recruited patients receiving immune checkpoint blockade (ICB) for melanoma. CMV+ patients with metastatic melanoma (MM) have higher lymphocyte counts, reduced neutrophil to lymphocyte ratio and divergent CD8+ T cell gene expression. Combination anti-CTLA-4/anti-PD-1 ICB, but not single-agent anti-PD-1 ICB, induces cytotoxicity and CMV-associated gene expression in CD8+ T cells from CMV− patients. Correspondingly, overall survival was independent of CMV serostatus in combination anti-CTLA-4/anti-PD-1 ICB recipients (CMV+ hazard ratio for death: 1.02, P = 0.92), whereas CMV+ single-agent anti-PD-1 ICB recipients had improved overall survival (CMV+ hazard ratio for death: 0.37, P < 0.01), a finding also seen in CMV+ adjuvant single-agent anti-PD-1 ICB recipients (CMV+ hazard ratio for recurrence: 0.19, P = 0.03). We identify TBX21, encoding T-bet, as a transcriptional driver of CMV-associated CD8+ T cell gene expression, finding that TBX21 expression is predictive of overall survival (hazard ratio: 0.62, P = 0.026). CMV+ patients unexpectedly show reduced cumulative incidence of grade 3+ immune-related adverse events at 6 months (0.30 versus 0.52, P = 2.2 × 10−5), with lower incidence of colitis (P = 7.8 × 10−4) and pneumonitis (P = 0.028), an effect replicated in non-melanoma ICB recipients (n = 58, P = 0.044). Finally, we find reduced CMV seropositivity rates in patients with MM compared with UK Biobank controls (odds ratio: 0.52, P = 1.8 × 10−4), indicating CMV seropositivity may protect against MM. Specifically, patients with BRAF-mutated MM are less likely to be CMV+ (odds ratio = 2.2, P = 0.0054), while CMV− patients present 9 yr earlier with BRAF wild-type MM (P = 1.3 × 10−4). This work reveals an interaction between CMV infection, MM development according to BRAF status and response to ICB, while demonstrating CMV infection is protective against severe ICB immune-related adverse events, highlighting the potential importance of previous infection history and chronic immune activation in MM development and immunotherapy outcomes.


  • Open Access

    Defining the genetic determinants of CD8 + T cell receptor repertoire in the context of immune checkpoint blockade

    by Esther S. Ng, Orion Tong, Chelsea Alice Taylor, Robert Aerwyn Watson, Bo Sun, Gusztav Milotay, Sophie MacKay, James J Gilchrist, Martin Little, Benjamin Peter Fairfax, et al.

    CD8 + T cells play a central role in the cancer response to immune checkpoint blockade (ICB) treatment, with activity predicated upon antigen recognition by the associated T cell receptor (TCR) repertoire. The contribution of genetic variation to this in cancer treatment is under-explored. We have conducted a genome-wide and human leukocyte antigen (HLA)-focused analysis of CD8 + T cell TCR repertoire to identify genetic determinants of variable gene (V-gene) and CDR3 K-mer usage from samples taken prior to and after ICB treatment (n=250). We find 11 genome-wide significant cis associations and 10 trans associations, primarily to the HLA, with V-gene usage meeting permuted P-value thresholds. Notably, TCR clones containing V-genes associated with HLA were less likely to be persistent across treatment. In a single-cell experiment, we find cells with HLA-matched TCR clones have increased tumor reactivity expression profiles and patients with HLA-matched TCR clones have improved overall survival. Our work indicates a complex relationship between genotype and TCR repertoire in the context of treatment with ICB, which has novel implications for understanding determinants of treatment response and patient outcomes. One Sentence Summary: TCR repertoire is strongly associated with specific HLA alleles in cancer patients, but immune checkpoint blockade influences this association.

  • Open Access

    Cytomegalovirus infection protects against metastatic melanoma and modulates oncological outcome and toxicity to checkpoint immunotherapy

    by Gusztav Milotay, Martin Little, Robert Aerwyn Watson, Dylan Muldoon, Orion Tong, Chelsea Alice Taylor, Sophie MacKay, Isar Nassiri, Bo Sun, Louisa M Webb, et al.

    Summary Paragraph: The relationship between chronic viral infection and cancer response to immune checkpoint blockade (ICB) is poorly understood. Cytomegalovirus (CMV) infection is globally endemic and causes severe disease in the immunocompromised. In immunocompetent individuals the clinical effects of CMV infection are an area of active investigation. Here, in analysis of 396 patients receiving ICB for cancer, we investigate the oncological and immunological consequences of CMV seropositivity. We find that infection with CMV leads to profound skewing of CD8 + T cell subsets towards an effector phenotype, divergence in gene expression, increased total lymphocyte count and reduced neutrophil:lymphocyte ratio. These differences are associated with immunologically distinct responses to ICB in patients with metastatic melanoma (MM). We identify a gene set highly-associated with CMV infection which is robustly induced by combination ICB (anti-CTLA-4 + anti-PD-1, cICB) but not by single-agent anti-PD-1 (sICB) in CMV seronegative individuals. Consequently, CMV seropositivity is associated with prolonged Overall Survival (OS) in those treated with sICB (HR 0.49, P.01) whereas there is no observed survival association of CMV following cICB treatment (HR 0.95, P=.82). We demon-strate these CMV-determined divergent effects are driven by expression of TBX21 , encoding the transcription factor T-bet. Expression of TBX21 predicts OS across all patients (HR 0.67, P=0.013 for above-median expression), with durable response to ICB associated with induction of expanded TBX21 expressing CD8 + clones. Unexpectedly, we find CMV infection is associated with reduced cumulative incidence of Grade 3+ immune related adverse events (irAEs) at 6 months (0.31 vs. 0.53, P=2.1×10 −5 ), notably lowering incidence of colitis (P=.00095) and pneumonitis (P=.026), with infected patients requiring fewer steroids or second line immunosuppressants. Finally we link CMV infection to protection against MM, demonstrating lower seropositivity rates in patients with MM, but not early Stage II/III disease, compared to population controls from the UK biobank (OR 0.53, P=.00016). CMV protection is contingent upon melanoma BRAF mutation status, with CMV being associated with reduced development of MM in BRAF mutated patients and later presentation of BRAF wild-type MM. This work reveals a previously unrecognised interaction between CMV infection, melanoma muta-tional state, development of metastatic disease and response to ICB, as well as demonstrating CMV infection protects against ICB irAEs, underpinning the importance of prior infection history and chronic immune activation in development of MM and outcomes to immunotherapy. We anticipate other immunosensitive cancers may show similar interactions between chronic viral infection and response to ICB.

  • Open Access

    Peripheral monocyte transcriptomics associated with immune checkpoint blockade outcomes in metastatic melanoma

    by Rosalin A Cooper, Chelsea A Taylor, Robert A Watson, Orion Tong, Isar Nassiri, Piyush Kumar Sharma, Martin Little, Weiyu Ye, Surya Koturan, Sara Danielli, et al.

    Clinical responses to immune checkpoint blockade (ICB) for metastatic melanoma (MM) are variable, with patients frequently developing immune related adverse events (irAEs). The role played by myeloid populations in modulating responses to ICB remains poorly defined. We explored the effect of MM and the response to ICB across a cohort of patients with MM (n=116) and healthy donors (n=45) using bulk and single cell RNA-seq, and flow cytometry. Monocytes from patients with MM exhibit highly dysregulated baseline transcriptional profiles, whilst ICB treatment elicits induction of interferon signaling, MHC class II antigen presentation and CXCR3 ligand expression. Although both combination (cICB - anti-PD-1 and anti-CTLA) and single-agent (sICB - anti-PD1) ICB therapy modulates a shared set of genes, cICB displays a markedly greater magnitude of transcriptional effect. Notably, we find increased baseline monocyte counts correlate with a monocyte proliferation signature and risk of early death, whilst a gene-signature corresponding to a subset of platelet-binding classical monocytes conversely associates with improved outcome. This work demonstrates a central role for monocytes in the modulation of treatment response to ICB, providing insights into inter-individual variation in immune responses to ICB and further highlighting the multifarious immunological consequences of ICB treatment.